文献速递神经肿瘤

c-Met表达对IDH突变低级别胶质瘤和IDH野生型胶质母细胞瘤的预后预测价值

c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
PubMed 文献 · World Neurosurg · 2019-03-13

该研究分析了153例WHO II-IV级弥漫性星形细胞和少突胶质细胞肿瘤患者的c-Met表达与临床病理特征及预后的相关性。结果显示c-Met表达在少突胶质细胞肿瘤和IDH野生型胶质母细胞瘤中与无进展生存期相关,并在多个亚型中与总生存期相关。结论认为c-Met表达是IDH突变低级别胶质瘤和IDH野生型胶质母细胞瘤预后预测的有用标志物。

要点

  • c-Met表达与少突胶质细胞肿瘤和IDH野生型胶质母细胞瘤的无进展生存期相关。
  • c-Met表达与间变性少突胶质细胞瘤、少突胶质细胞肿瘤、IDH突变型弥漫性星形细胞瘤、IDH野生型弥漫性星形细胞瘤和IDH野生型胶质母细胞瘤的总生存期相关。
  • c-Met表达在IDH突变型低级别星形细胞肿瘤中与总生存期有相关趋势。

核心结论

  • c-Met表达是IDH突变低级别胶质瘤和IDH野生型胶质母细胞瘤预后预测的有用标志物,是一种易于测量的新独立预后标志物。

研究设计与样本

  • 对153例组织学定义的WHO II-IV级弥漫性星形细胞和少突胶质细胞肿瘤患者进行分析。

主要发现

  • 少突胶质细胞瘤(IDH突变伴1p19q共缺失)16例,c-Met阳性率6.3%;间变性少突胶质细胞瘤(IDH突变伴1p19q共缺失)11例,阳性率36.4%;弥漫性星形细胞瘤(IDH突变)21例,阳性率28.6%;间变性星形细胞瘤(IDH突变)15例,阳性率20%;胶质母细胞瘤(IDH突变)2例,阳性率100%;弥漫性星形细胞瘤(IDH野生型)9例,阳性率33.3%;间变性星形细胞瘤(IDH野生型)20例,阳性率30.0%;胶质母细胞瘤(IDH野生型)59例,阳性率52.5%。
  • c-Met表达与少突胶质细胞肿瘤和IDH野生型胶质母细胞瘤的无进展生存期相关。
  • c-Met表达与间变性少突胶质细胞瘤、少突胶质细胞肿瘤、IDH突变型弥漫性星形细胞瘤、IDH野生型弥漫性星形细胞瘤和IDH野生型胶质母细胞瘤的总生存期相关,并在IDH突变低级别星形细胞肿瘤中与总生存期有相关趋势。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. METHODS: A total of 153 patients with histologically defined World Health Organization grade II-IV diffuse astrocytic and oligodendroglial tumors were analyzed. RESULTS: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. CONCLUSIONS: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ohba S, Yamada Y, Murayama K, et al. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. World Neurosurg. 2019. PMID: 30878754. doi:10.1016/j.wneu.2019.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。